Search - tctmd.com

Displaying 181 - 200 of 3565

Sort: Relevancy | Date

Presentation TCT 2016

Key Contributions to TAVR Clinical Research III: Updates From Italian Registries and OBSERVANT

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Corrado Tamburino

October 30, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research II: Updates From the UK TAVR Registry

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Neil E. Moat

October 30, 2016

Presentation TCT 2016

Key Contributions to TAVR Clinical Research I: Updates From GARY and Other German Registries

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Thomas Walther

October 30, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease II. TAVR in Patients With Acute and Chronic Coronary Syndromes - When and How Much to Treat

Presenter: A. Pieter Kappetein, Allan Schwartz, James B. Hermiller Jr.

October 30, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease I. TAVR in Patients With Mitral Regurgitation - Outcomes and Management Strategies (Including MitraClip)

Presenter: A. Pieter Kappetein, Allan Schwartz, Marco Barbanti

October 30, 2016

Presentation TCT 2016

Paravalvular Regurgitation - The Achilles Heel or Problem Solved: Latest Updates on the Assessment of Paravalvular Regurgitation (Aortic and Mitral)

Presenter: Carlos E. Ruiz, Ulrich Steinseifer, Rebecca T. Hahn

October 30, 2016

Presentation TCT 2016

Symptomatic High-Risk Aortic Regurgitation: Is TAVR A Viable Alternative?

Presenter: A. Pieter Kappetein, Allan Schwartz, Hendrik Treede

October 30, 2016

Presentation TCT 2016

Comments and What I Might Have Done Differently

Presenter: Ricardo Lluberas, Jeffrey W. Moses, Jamil Abdalla Saad, Jose Armando Mangione

October 30, 2016

Presentation TCT 2016

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Presenter: A. Pieter Kappetein, Allan Schwartz, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Case 4: A Patient With Severe Aortic Valve Stenosis and Intermediate Surgical Risk. How Did I Treat It?

Presenter: Ricardo Lluberas, Jeffrey W. Moses, Jamil Abdalla Saad, Antonio Enrique Dager

October 30, 2016

Presentation TCT 2016

Low-Flow Aortic Stenosis: Clinical Outcomes After TAVR

Presenter: A. Pieter Kappetein, Allan Schwartz, Howard C. Herrmann

October 30, 2016

Presentation TCT 2016

TCT 1559: TMVR Using a Fully Repositionable (LOTUS) Valve in a Patient With Severe MAC, Septal Hypertrophy, Left Main Disease, and Severe Aortic Stenosis: Importance of Preprocedural Planning

Presenter: Henrique B. Ribeiro, Dimytri Alexandre Siqueira, Chris Meduri

October 30, 2016

Presentation TCT 2016

Low-Flow Aortic Stenosis: Pathophysiology, Syndrome Classification, and Prognosis

Presenter: A. Pieter Kappetein, Allan Schwartz, Philippe Pibarot

October 30, 2016

Presentation TCT 2016

Transcatheter Valve-in-Valve Therapy: Clinical and Technical Pearls

Presenter: A. Pieter Kappetein, Allan Schwartz, Vinayak Bapat

October 30, 2016

Presentation TCT 2016

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Presenter: A. Pieter Kappetein, Allan Schwartz, Danny Dvir

October 30, 2016

Presentation TCT 2016

TAVR Outcomes and Technical Pearls in Bicuspid Aortic Stenosis (With Case Examples)

Presenter: A. Pieter Kappetein, Allan Schwartz, Mathew Williams

October 30, 2016

Presentation TCT 2016

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

Presenter: A. Pieter Kappetein, Allan Schwartz, Lars Sondergaard

October 30, 2016

Presentation TCT 2016

Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR!

Presenter: Russell A. Brandwein, Isaac George

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, David J. Cohen

October 30, 2016

Advertisement

Key Contributions to TAVR Clinical Research III: Updates From Italian Registries and OBSERVANT

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Key Contributions to TAVR Clinical Research II: Updates From the UK TAVR Registry

Key Contributions to TAVR Clinical Research I: Updates From GARY and Other German Registries

Aortic Stenosis + Concomitant Disease II. TAVR in Patients With Acute and Chronic Coronary Syndromes - When and How Much to Treat

Aortic Stenosis + Concomitant Disease I. TAVR in Patients With Mitral Regurgitation - Outcomes and Management Strategies (Including MitraClip)

Paravalvular Regurgitation - The Achilles Heel or Problem Solved: Latest Updates on the Assessment of Paravalvular Regurgitation (Aortic and Mitral)

Symptomatic High-Risk Aortic Regurgitation: Is TAVR A Viable Alternative?

Comments and What I Might Have Done Differently

Moderate Aortic Stenosis + Heart Failure: Introduction to the UNLOAD Trial

Case 4: A Patient With Severe Aortic Valve Stenosis and Intermediate Surgical Risk. How Did I Treat It?

Low-Flow Aortic Stenosis: Clinical Outcomes After TAVR

TCT 1559: TMVR Using a Fully Repositionable (LOTUS) Valve in a Patient With Severe MAC, Septal Hypertrophy, Left Main Disease, and Severe Aortic Stenosis: Importance of Preprocedural Planning

Low-Flow Aortic Stenosis: Pathophysiology, Syndrome Classification, and Prognosis

Transcatheter Valve-in-Valve Therapy: Clinical and Technical Pearls

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

TAVR Outcomes and Technical Pearls in Bicuspid Aortic Stenosis (With Case Examples)

Bicuspid Aortic Valve Disease: Epidemiology, Anatomy, Classification, and Special Considerations for TAVR

Debate: TAVR for Low Risk Patients Is It time? NO, We Dont Yet Know if Its as Durable as Surgical AVR!

Flash Debate: Counterpoint The Emergence of TAVR Risk Scores Are a Better Solution to Patient Selection!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content